198 related articles for article (PubMed ID: 28691344)
1. Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
Bubien V; Bonnet F; Dupiot-Chiron J; Barouk-Simonet E; Jones N; de Reynies A; MacGrogan G; Sevenet N; Letouzé E; Longy M
Genes Chromosomes Cancer; 2017 Nov; 56(11):788-799. PubMed ID: 28691344
[TBL] [Abstract][Full Text] [Related]
2. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
Tavera-Tapia A; Pérez-Cabornero L; Macías JA; Ceballos MI; Roncador G; de la Hoya M; Barroso A; Felipe-Ponce V; Serrano-Blanch R; Hinojo C; Miramar-Gallart MD; Urioste M; Caldés T; Santillan-Garzón S; Benitez J; Osorio A
Breast Cancer Res Treat; 2017 Feb; 161(3):597-604. PubMed ID: 27913932
[TBL] [Abstract][Full Text] [Related]
3. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.
Sierra-Díaz DC; Morel A; Fonseca-Mendoza DJ; Bravo NC; Molano-Gonzalez N; Borras M; Munevar I; Lema M; Idrobo H; Trujillo D; Serrano N; Orduz AI; Lopera D; González J; Rojas G; Londono-De Los Ríos P; Manneh R; Cabrera R; Rubiano W; de la Peña J; Quintero MC; Mantilla W; Restrepo CM
Hum Genomics; 2024 Jun; 18(1):68. PubMed ID: 38890714
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing of Finnish hereditary breast cancer families.
Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
[TBL] [Abstract][Full Text] [Related]
6. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
[TBL] [Abstract][Full Text] [Related]
7. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
Hilbers FS; Meijers CM; Laros JF; van Galen M; Hoogerbrugge N; Vasen HF; Nederlof PM; Wijnen JT; van Asperen CJ; Devilee P
PLoS One; 2013; 8(1):e55734. PubMed ID: 23383274
[TBL] [Abstract][Full Text] [Related]
9. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
Prodosmo A; Buffone A; Mattioni M; Barnabei A; Persichetti A; De Leo A; Appetecchia M; Nicolussi A; Coppa A; Sciacchitano S; Giordano C; Pinnarò P; Sanguineti G; Strigari L; Alessandrini G; Facciolo F; Cosimelli M; Grazi GL; Corrado G; Vizza E; Giannini G; Soddu S
J Exp Clin Cancer Res; 2016 Sep; 35(1):135. PubMed ID: 27599564
[TBL] [Abstract][Full Text] [Related]
10. Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
Rouleau E; Jesson B; Briaux A; Nogues C; Chabaud V; Demange L; Sokolowska J; Coulet F; Barouk-Simonet E; Bignon YJ; Bonnet F; Bourdon V; Bronner M; Caputo S; Castera L; Delnatte C; Delvincourt C; Fournier J; Hardouin A; Muller D; Peyrat JP; Toulas C; Uhrhammer N; Vidal V; Stoppa-Lyonnet D; Bieche I; Lidereau R
Breast Cancer Res Treat; 2012 Jun; 133(3):1179-90. PubMed ID: 22476849
[TBL] [Abstract][Full Text] [Related]
11. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
12. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of deleterious ATM germline mutations in gastric cancer patients.
Huang DS; Tao HQ; He XJ; Long M; Yu S; Xia YJ; Wei Z; Xiong Z; Jones S; He Y; Yan H; Wang X
Oncotarget; 2015 Dec; 6(38):40953-8. PubMed ID: 26506520
[TBL] [Abstract][Full Text] [Related]
14. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
[TBL] [Abstract][Full Text] [Related]
15. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
[TBL] [Abstract][Full Text] [Related]
16. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
17. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing in familial breast cancer patients from Lebanon.
Jalkh N; Chouery E; Haidar Z; Khater C; Atallah D; Ali H; Marafie MJ; Al-Mulla MR; Al-Mulla F; Megarbane A
BMC Med Genomics; 2017 Feb; 10(1):8. PubMed ID: 28202063
[TBL] [Abstract][Full Text] [Related]
20. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
